Gene synthesis offers solutions in synthetic biology for creating artificial genes in vitro with the help of solid phase DNA synthesis. Global gene synthesis market is expected to rise with a CAGR of 17.4% during the forecast year 2019-2026. Significant decrease in the cost of gene synthesis has promoted the demand in drug development, research activities, therapies, diagnostics etc. and has thus fuelled immense growth in the market.
Advent of revolutionary technologies such as CRISPR cas9 have brought a paradigmatic shift in the market by lowering the cost of gene synthesis and sequencing. According to the National Human Genome Research Institute (NHGRI), cost per raw mega base of DNA sequences has decreased from over $10,000 in 2001 to less than $1000 as of year 2017. Moreover, cost per genome has been estimated to lower from about $100 million to below $1000 during 2001-2017 respectively. This revolutionary change has boosted the demand for gene sequencing and synthesis. Furthermore, increased adoption of gene synthesis in personalized medicine and surging number of start-ups has also helped to drive the growth of the market.
Global gene synthesis market has been segmented based on products and services, applications, end user and method. Based on product and services, the market has been segmented into consumables, software and services. Furthermore, end users in the market cover academic and research institutes, biopharmaceutical companies, contract research organizations, etc. Biopharmaceutical companies dominate the market when it comes to end users owing to the rising demand of gene synthesis in drug discovery and development. Taking into consideration the methods, the market has been segmented into solid phase synthesis, chip-based DNA synthesis, PCR-based enzyme synthesis, microchip-based oligonucleotide synthesis.
Regional segmentation of the gene synthesis market includes North America, Europe, Asia Pacific and the rest of the world. North America dominates the market due to risen utilization of gene synthesis in the development of personalized medicine. For instance, as per the personalized medicine coalition, as of a 2018 survey, one in every four drugs is approved in the US by US Food and Drug Administration accounts for personalized medicine. Asia Pacific is expected to show rapid growth owing to the extensive genomics research and increasing number of gene synthesis based start-ups in the developing countries such as India, China and South Korea.
Major players across the market include Merck KGaA, Eurofins Genomics, Genscript Biotech Corp., Thermo Fisher Scientific Inc. (GeneArt), ATUM (DNA2.0 Inc.) and others. These companies are using various strategies such as collaboration, partnership, merger & acquisition, technology transfer and product launch. For instance, on 8th April 2019, Genscript Biotech Corp. a prime gene synthesis provider announced the launch of a public beta testing program for their precision mutant library services that is expected to be applied in industrial, chemical, drug development and synthetic biology. The service offers to determine the distribution of each codon resulting in a diverse library by utilizing advanced semiconductor-based oligonucleotide synthesis technology.